Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101283 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00101283 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 32 participants.
The verdict
NCT00101283, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving pemetrexed disodium with gemcitabine is more effective than giving pemetrexed disodium with carboplatin in treating malignant pleural mesothelioma. PURPOSE: This randomized phase II trial is studying pemetrexed disodium with gemcitabine and pemetrexed disodium with carboplatin to see how well the combinations work compared to historical controls in treating patients with advanced malignant pleural mesothelioma.
Interventions
- DRUG carboplatin
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-02-23 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101283
The ClinicalTrials.gov registry entry for NCT00101283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00101283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101283 about?
NCT00101283 is a clinical study titled "Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma". RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. I...
What is the current status of trial NCT00101283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-02-23. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00101283?
The interventions under investigation include: carboplatin (DRUG), gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00101283?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.